CAJ | 학술논문

目的探讨髓过氧化物酶(cMPO)在急性髓系白血病(AML)患者中的表达及其在诊断分型中的意义.方法采用CD45/SSC双参数散点图设门方法对502例AML患者进行八色流式细胞术免疫表型分析,观察患者白血病细胞cMPO表达的阳性率和阳性强度.结果 502例AML患者cMPO总体阳性率为58.0％,其中阳性占21.5％,弱阳性占34.1％,部分阳性占2.4％;阴性占42.0％.各亚型中,AML伴t(15;17) (q22;q 12)/PML-RARα的cMPO阳性率最高,为100％,阳性强度多数接近正常粒细胞水平;其次为AML伴t(8;21) (q22;q22)/RUNX 1-RUNX1T1,阳性率为91.4％,阳性强度多为弱阳性;AML微分化型和急性巨核细胞白血病患者cMPO表达皆为阴性;余各亚型阳性率在22.7％～76.2％.结论各亚型AML cMPO的阳性率及阳性强度存在显著差异.
목적 탐토수과양화물매(cMPO)재급성수계백혈병(AML)환자중적표체급기재진단분형중적의의.방법 채용CD45/SSC쌍삼수산점도설문방법대502례AML환자진행팔색류식세포술면역표형분석,관찰환자백혈병세포cMPO표체적양성솔화양성강도.결과 502례AML환자cMPO총체양성솔위58.0％,기중양성점21.5％,약양성점34.1％,부분양성점2.4％;음성점42.0％.각아형중,AML반t(15;17) (q22;q 12)/PML-RARα적cMPO양성솔최고,위100％,양성강도다수접근정상립세포수평;기차위AML반t(8;21) (q22;q22)/RUNX 1-RUNX1T1,양성솔위91.4％,양성강도다위약양성;AML미분화형화급성거핵세포백혈병환자cMPO표체개위음성;여각아형양성솔재22.7％～76.2％.결론 각아형AML cMPO적양성솔급양성강도존재현저차이.
Objective To investigate the myeloperoxidase (cMPO) expression pattern by flow cytometry (FCM) in patients with acute myeloid leukemia (AML) and its role in classifying AML.Methods Eight-color multiparametric FCM with CD45/SSC gating was used to determine the cMPO expression in 502 AML patients.Results The positive rate of cMPO in all patients was 58.0％,in which the proportion of normal positivity,dim positivity and partial positivity was 21.5％,34.1％ and 2.4％,respectively.The remaining cases (42.0％) were all negative.In AML with t (15;17) (q22;q12)/PML-RARαt,the positive rate was the highest (100％) and the intensity was similar to that of the normal granular leukocytes,followed by AML with t(8;21) (q22;q22)/RUNX1-RUNX1T1,the positive rate was 91.4％ and the intensity was mostly dim.AML with minimal differentiation and acute megakaryoblastic leukemia were all cMPO negative.The positive rates of eMPO in the remaining subtypes were between 22.7％ and 76.2％.Conclusion The positive rate and intensity of cMPO were significantly different among different subtypes of AML.